These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23913215)

  • 1. Deep transcriptome profiling of ovarian cancer cells using next-generation sequencing approach.
    Li L; Liu J; Yu W; Lou X; Huang B; Lin B
    Methods Mol Biol; 2013; 1049():139-69. PubMed ID: 23913215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies.
    Cheng L; Lu W; Kulkarni B; Pejovic T; Yan X; Chiang JH; Hood L; Odunsi K; Lin B
    Gynecol Oncol; 2010 May; 117(2):159-69. PubMed ID: 20181382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
    Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
    Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
    Konno R
    Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray-based transcriptome profiling of ovarian cancer cells.
    Cui J; Xu Y; Puett D
    Methods Mol Biol; 2013; 1049():119-37. PubMed ID: 23913214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
    Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
    Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
    Yang L; Li N; Wang H; Jia X; Wang X; Luo J
    Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
    Cheng TC; Manorek G; Samimi G; Lin X; Berry CC; Howell SB
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):384-95. PubMed ID: 16404635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment.
    Roth SA; Knutsen E; Fiskaa T; Utnes P; Bhavsar S; Hald ØH; Løkke C; Mestdagh P; Johansen SD; Flægstad T; Einvik C
    Cancer Lett; 2016 Mar; 372(1):128-36. PubMed ID: 26708804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis.
    Li L; Luan Y; Li X; Tang B; Zhang W; Li D; Zhao J; Wang G; Ding H; Reed E; Li QQ
    Oncol Rep; 2005 May; 13(5):793-9. PubMed ID: 15809740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT; Ong CK; Tay SK; Huynh H
    Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for genes associated with ovarian cancer prognosis.
    Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
    Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of platinum resistant ovarian cancer: use of the model in clinical practice.
    Gevaert O; Pochet N; De Smet F; Van Gorp T; De Moor B; Timmerman D; Amant F; Vergote I
    Int J Cancer; 2006 Sep; 119(6):1511; author reply 1512. PubMed ID: 16619247
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.